Medication info

Rozakan Plus Tablet

Prescription medicationTabletOralExpired
Ingredient · strength
Losartan Potassium›50mg / 1 tabletHydrochlorothiazide›12.5mg / 1 tablet
Manufacturer / importer
Youngjin Pharmaceutical Co., Ltd.
Appearance
Yellow oval film-coated tablet
Packaging
30 tablets/bottle, 100 tablets/bottle
Approval status
Expired

MFDS item code 200800219 · Notified 2008.01.07

This product's status changed to Expired on 2024.07.01. It may no longer be sold, so consult a doctor or pharmacist before taking it.

Summary

Main use
Treatment of hypertension not controlled with monotherapy
Who takes it
Adults · Children
Adult dose
○ Adults The usual dose of this drug is 1 tablet containing 50 mg of losartan potassium/12.5 mg of hydrochlorothiazide once daily. A daily dose exceeding 100 mg of losartan potassium/25 mg of hydrochlorothiazide is not recommended. The maximum blood pressure-lowering effect generally occurs around 3 weeks after starting treatment. This drug may be administered with other antihypertensive agents and may be taken with or without food. To minimize adverse reactions, start this drug when the expected effect is not achieved with monotherapy. 1. Substitution therapy: The combination of individually titrated doses of losartan potassium and hydrochlorothiazide may be replaced with this drug. 2. Patients whose blood pressure is not controlled with losartan or hydrochlorothiazide monotherapy: Start with 1 tablet of losartan potassium 50 mg/hydrochlorothiazide 12.5 mg once daily. If blood pressure remains uncontrolled after 3 weeks of treatment, the dose may be increased to a maximum of 1 tablet of losartan potassium 100 mg/hydrochlorothiazide 25 mg once daily. 3. Patients whose blood pressure is not controlled with losartan potassium 100 mg monotherapy: Start with losartan potassium 100 mg/hydrochlorothiazide 12.5 mg once daily. If blood pressure remains uncontrolled after 3 weeks of treatment, the dose may be increased to a maximum of 1 tablet of losartan potassium 100 mg/hydrochlorothiazide 25 mg once daily. 4. Patients whose blood pressure is not controlled with hydrochlorothiazide 25 mg once daily, or who have hypokalemia even when blood pressure is controlled with this dose: Treatment may be started with 1 tablet of losartan potassium 50 mg/hydrochlorothiazide 12.5 mg once daily, which can reduce the hydrochlorothiazide dose without reducing the overall blood pressure-lowering effect. Continue to assess the clinical response to losartan potassium 50 mg/hydrochlorothiazide 12.5 mg, and if blood pressure remains uncontrolled after 3 weeks of treatment, the dose may be increased to a maximum of 1 tablet of losartan potassium 100 mg/hydrochlorothiazide 25 mg once daily. ○ Patients with renal impairment Use the usual dose if creatinine clearance is 30 mL/min or higher. Use of this drug is not recommended in patients with more severe renal impairment, because loop diuretics are preferable to thiazide drugs in these patients. ○ Patients with hepatic impairment The initial dose of losartan potassium for patients with hepatic impairment requiring dosage adjustment is 25 mg, which cannot be administered using this drug; therefore, use of this drug is not recommended in these patients.
Child dose
○ Children (under 18 years) There is no experience with use in children and adolescents; therefore, the losartan-hydrochlorothiazide combination should not be administered to children or adolescents.

Ingredients

Manufacturer
Youngjin Pharmaceutical Co., Ltd.

Efficacy & effects

Treatment of hypertension not controlled with monotherapy

  • Hypertension
View approved original text

This medication is used for the treatment of hypertension when blood pressure is not adequately controlled with monotherapy.

How to take

Adult dose

○ Adults The usual dose of this drug is 1 tablet containing 50 mg of losartan potassium/12.5 mg of hydrochlorothiazide once daily. A daily dose exceeding 100 mg of losartan potassium/25 mg of hydrochlorothiazide is not recommended. The maximum blood pressure-lowering effect generally occurs around 3 weeks after starting treatment. This drug may be administered with other antihypertensive agents and may be taken with or without food. To minimize adverse reactions, start this drug when the expected effect is not achieved with monotherapy. 1. Substitution therapy: The combination of individually titrated doses of losartan potassium and hydrochlorothiazide may be replaced with this drug. 2. Patients whose blood pressure is not controlled with losartan or hydrochlorothiazide monotherapy: Start with 1 tablet of losartan potassium 50 mg/hydrochlorothiazide 12.5 mg once daily. If blood pressure remains uncontrolled after 3 weeks of treatment, the dose may be increased to a maximum of 1 tablet of losartan potassium 100 mg/hydrochlorothiazide 25 mg once daily. 3. Patients whose blood pressure is not controlled with losartan potassium 100 mg monotherapy: Start with losartan potassium 100 mg/hydrochlorothiazide 12.5 mg once daily. If blood pressure remains uncontrolled after 3 weeks of treatment, the dose may be increased to a maximum of 1 tablet of losartan potassium 100 mg/hydrochlorothiazide 25 mg once daily. 4. Patients whose blood pressure is not controlled with hydrochlorothiazide 25 mg once daily, or who have hypokalemia even when blood pressure is controlled with this dose: Treatment may be started with 1 tablet of losartan potassium 50 mg/hydrochlorothiazide 12.5 mg once daily, which can reduce the hydrochlorothiazide dose without reducing the overall blood pressure-lowering effect. Continue to assess the clinical response to losartan potassium 50 mg/hydrochlorothiazide 12.5 mg, and if blood pressure remains uncontrolled after 3 weeks of treatment, the dose may be increased to a maximum of 1 tablet of losartan potassium 100 mg/hydrochlorothiazide 25 mg once daily. ○ Patients with renal impairment Use the usual dose if creatinine clearance is 30 mL/min or higher. Use of this drug is not recommended in patients with more severe renal impairment, because loop diuretics are preferable to thiazide drugs in these patients. ○ Patients with hepatic impairment The initial dose of losartan potassium for patients with hepatic impairment requiring dosage adjustment is 25 mg, which cannot be administered using this drug; therefore, use of this drug is not recommended in these patients.

Child dose

○ Children (under 18 years) There is no experience with use in children and adolescents; therefore, the losartan-hydrochlorothiazide combination should not be administered to children or adolescents.

Precautions

This medication can severely harm the fetus when taken during pregnancy, especially in the second and third trimesters, so it should be discontinued immediately once pregnancy is confirmed. Patients with allergies to this medication, severely impaired kidney function, severe liver disease, or pregnant women should not take it. Caution should be exercised when taking this medication in older adults or individuals with diseases such as hypotension, kidney dysfunction, liver disease, electrolyte imbalance, diabetes, or gout, and regular testing is required. This medication lowers blood pressure and may cause dizziness or drowsiness, so care should be taken when driving or operating machinery. As it may affect potassium levels, potassium supplements or potassium-containing medications should not be taken without consulting a physician. It is important to regularly check kidney function and electrolyte status through blood tests while taking this medication. Due to the hydrochlorothiazide component, skin may become sensitive to sunlight, so exposure to sunlight should be avoided, and attention should be paid to ultraviolet protection. This medication can interact with other medications, so it is essential to inform healthcare professionals about any other drugs being taken, especially when combined with diuretics, antihypertensives, lithium, and non-steroidal anti-inflammatory drugs (NSAIDs). In case of overdose, hypotension or arrhythmias may occur, so immediate medical attention is required. This medication is not recommended for use in children and adolescents, as safety and efficacy have not been established. If unusual symptoms or discomfort occur during use, immediately consult a physician or pharmacist.

Side effects

  • Craniosynostosis
  • anuria
  • hypotension
  • renal failure
  • death
  • abdominal pain
  • edema
  • palpitations
  • back pain
  • dizziness
Show 127 more
  • cough
  • sinusitis
  • upper respiratory infection
  • rash
  • angioedema
  • skin peeling
  • hemolysis
  • chest pain
  • facial swelling
  • fever
  • orthostatic hypotension
  • syncope
  • angina
  • arrhythmia
  • cerebrovascular accident
  • myocardial infarction
  • secondary atrioventricular block
  • loss of appetite
  • constipation
  • toothache
  • dry mouth
  • dyspepsia
  • flatulence
  • gastritis
  • vomiting
  • lethargy
  • anemia
  • gout
  • arm pain
  • arthralgia
  • arthritis
  • fibromyalgia
  • hip pain
  • joint swelling
  • knee pain
  • leg pain
  • muscle cramps
  • muscle weakness
  • musculoskeletal pain
  • myalgia
  • shoulder pain
  • muscle stiffness
  • anxiety
  • anxiety disorder
  • ataxia
  • confusion
  • depression
  • nightmares
  • sensory impairment
  • insomnia
  • loss of libido
  • memory impairment
  • migraine
  • irritability
  • panic disorder
  • sensory abnormalities
  • peripheral neuropathy
  • sleep disorder
  • drowsiness
  • tremor
  • dyspnea
  • nasal hemorrhage
  • nasal congestion
  • pharyngeal discomfort
  • respiratory congestion
  • rhinitis
  • venous sinus disorder
  • chest discomfort
  • alopecia
  • dermatitis
  • dry skin
  • petechiae
  • erythema
  • flushing
  • photosensitivity reaction
  • pruritus
  • sweating
  • urticaria
  • blurred vision
  • ocular pain
  • burning sensation
  • conjunctivitis
  • visual impairment
  • taste disorder
  • tinnitus
  • erectile dysfunction
  • nocturia
  • polyuria
  • urinary tract infection
  • weakness
  • pancreatitis
  • jaundice
  • sialadenitis
  • convulsion
  • gastrointestinal irritation
  • aplastic anemia
  • agranulocytosis
  • leukopenia
  • thrombocytopenia
  • purpura
  • necrotizing vasculitis
  • pneumonia
  • pulmonary edema
  • hyperglycemia
  • diabetes
  • hyperuricemia
  • muscle spasms
  • agitation
  • renal failure
  • renal impairment
  • interstitial nephritis
  • Stevens-Johnson syndrome
  • erythema multiforme
  • toxic epidermal necrolysis
  • transient blurred vision
  • yellow vision
  • acute myopia
  • acute closed-angle glaucoma
  • thrombocytopenia
  • vasculitis
  • anaphylactic reaction
  • hepatitis
  • dry cough
  • erythroderma
  • hyperkalemia
  • hyponatremia
  • rhabdomyolysis

Not everyone experiences these, and they can vary from person to person.

Storage

This medication is sensitive to light, so it should be stored in a container that does not allow light to enter. Additionally, it should be stored at room temperature between 1 to 30 degrees Celsius. This will help maintain the medication's efficacy.

Appearance and packaging

Appearance

Yellow oval film-coated tablet

Package unit

30 tablets/bottle, 100 tablets/bottle

Same-ingredient medicines

Even with the same ingredient, strength, dosage form and how it is taken can differ.

Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.

Questions about this medicine

No questions yet.

For anything that needs medical judgment, consult a doctor or pharmacist.

Related searches

Search tags

Suggested searches

This drug information is based on data provided by the Korea Ministry of Food and Drug Safety.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.